Underlying EBITDA rose 2.7% year-over-year to $38.6m, with strong operating cash flow and capital gains, but reported a net loss due to impairments and higher interest. Focus remains on sales execution, portfolio modernization, and reducing gearing.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.